IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer
WILMINGTON, Del.--(BUSINESS WIRE)--Oct 21, 2023--
Source: joplinglobe.com